Vector Biomed

Other Pharmaceuticals and Biotechnology

Vector Biomed is a private other pharmaceuticals and biotechnology company. It has raised $15 million across 1 recorded round; the latest was a $15 million Series A in Jan 2023.

Last price · $/share
—
Implied valuation
—
Total raised
$15.0M
Last round
Early Stage VC (Series A)
Jan 2023
Valuation — not yet established

No valuation for Vector Biomed is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($15.0M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Vector Biomed with a free account
  • ·Watch Vector Biomed: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vector Biomed funding history

1 rounds
DateRoundRaisedPost-money
Jan 2023Early Stage VC (Series A)$15.0M▮
Unlock post-money valuations

Membership and data by Private Market View

How much has Vector Biomed raised?

Vector Biomed has raised $15 million across 1 recorded round since 2023. The largest was a $15 million Series A in Jan 2023.

Vector Biomed has filed 1 Form D with the SEC, most recently in Dec 2022 ($7.5 million sold to 3 investors).

How Vector Biomed's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Vector Biomed, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Vector Biomed

How much has Vector Biomed raised?
Vector Biomed has raised $15.0M in total funding across 1 recorded rounds.
When did Vector Biomed last raise?
Vector Biomed last raised in Jan 2023 (Early Stage VC (Series A)), raising $15.0M.